Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6355MR)

This product GTTS-WQ6355MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6355MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1087MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ7719MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ6958MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ11395MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ9371MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ3702MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ864MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ15944MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW